$AVXL: Anavex signs a material transfer agreement
Post# of 22707
![Avatar](/images/ProfileImages/930245149_8857_Penguins.jpg)
"Battling demyelinating diseases such as multiple sclerosis requires an understanding of the processes that cause remyelination to fail. Remyelination of demyelinated axons is typically a function of oligodendrocyte precursor cells. These studies will examine the therapeutic role ANAVEX 2-73 may play in permitting remyelination in the brain," said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)